In response to the findings, the World Health Organization (WHO) has suspended testing of hydroxychloroquine in its so-called Solidarity Trial, a project set up to test the efficacy of this and three other drugs as treatments for COVID-19.
The trials were put on hold following the publication of a study in medical journal The Lancet last week, that suggests the drug does not help treat COVID-19 and in fact may cause heart problems or a greater risk of death in patients.
The trial, which was announced in mid-April, is a collaboration between the U of C, University of Alberta, Alberta Health Services and the provincial government.
The French government advisory body reviewed the latest data available, including the study published in The Lancet last week, and recommended against using hydroxychloroquine, alone or in combination, to treat Covid-19.
It comes after the World Health Organsiation (WHO) paused a large trial fo the drug because of safety concerns. The medicine was being tried and looked at in several other countries as a potential treatment for COVID-19, Paul said.
The WHO had said on Monday that it was halting clinical trials on the anti-malaria drug because of safety fears.
Last week, the study in the Lancet analysed data from almost 15,000 patients with Covid-19 who received the drug alone or in combination with antibiotics, against a control group of 81,000 who did not receive it.
"Whether [in doctors offices] in the cities or in the hospital, this. should not be prescribed for patients with COVID-19", the ministry said in a statement following the decree, according to Politico. Other countries, such as Spain, have made a decision to continue giving HCQ to coronavirus patients.
The drug, most often used to treat malaria, rose to prominence on March 19 when US President Donald Trump promoted the medication as a potential treatment for Covid-19.
Scientists have also stopped including the medicine in two major studies.
They urged that the drug not be used outside of clinical trials and added that "urgent confirmation from randomised clinical trials is needed".
France, Italy and Belgium have all halted hydroxychloroquine usage in COVID-19 treatments.
Other researchers say that the study doesn't take into account confounding factors that could sway mortality rates in the treatment group, such as doctors being more likely to prescribe experimental treatments to people who have more severe disease under compassionate use guidelines.